1. Home
  2. Ãéá ôïí áóèåíÞ
  3. ÊïéíùíéêÝò ðáñï÷Ýò
  4. Åðéäüìáôá

ÊïéíùíéêÝò ðáñï÷Ýò

ÌÝôñá êáé ÐñïãñÜììáôá Êïéíùíéêþí Ðáñï÷þí êáé Åíéó÷ýóåùí

  1. ÂéâëéÜñéï õãåßáò áðüñùí
  2. Éáôñï-öáñìáêåõôéêÞ êÜëõøç
  3. Åðéäüìáôá ãéá Üôïìá ìå HIV/AIDS

    ÏéêïíïìéêÞ åíßó÷õóç óå ðÜó÷ïíôåò áðü HIV/AIDS

    Áñìüäéá Õðçñåóßá: Äéåýèõíóç Ðñüíïéáò ôçò ïéêåßáò ÄçìïôéêÞò Áñ÷Þò (ÊáôÜëïãïò)

    ÄÉÊÁÉÏËÏÃÇÔÉÊÁ:

    1. Õðåýèõíç äÞëùóç Í. 1599/86*
    2. ÅðéêõñùìÝíï áíôßãñáöï äýï üøåùí áóôõíïìéêÞò ôáõôüôçôáò
    3. Ðéóôïðïéçôéêü ïéêïãåíåéáêÞò êáôÜóôáóçò (Áíáæçôåßôáé áõôåðÜããåëôá Þ ìðïñåß íá åêäï8åß ìÝóù Ê.Å.Ð.)
    4. Ðéóôïðïéçôéêü áíáðçñßáò 50% êáé Üíù áðü ÊÝíôñï Ðéóôïðïßçóçò Áíáðçñßáò (ÊÅÐÁ)
    5. Áñéèìüò ôñáðåæéêïý ëïãáñéáóìïý ÉÂÁÍ
    6. Áñéèìüò Öïñïëïãéêïý Ìçôñþïõ

    ÄÉÊÁÉÏÕ×ÏÉ:

    Äéêáéïý÷ïé åßíáé ïé åîÞò ìüíéìïé êÜôïéêïé ÅëëÜäáò:
    1. ¸ëëçíåò õðÞêïïé
    2. Êýðñéïé õðÞêïïé ðïõ Ý÷ïõí åëëçíéêÞ êáôáãùãÞ
    3. Åðáíáðáôñéæüìåíïé ïìïãåíåßò, Üó÷åôá áí Ý÷ïõí óôåñçèåß Þ ü÷é ôçò åëëçíéêÞò éèáãÝíåéáò
    4. ÕðÞêïïé ôùí Êñáôþí-Ìåëþí ôçò ÅõñùðáúêÞò ¸íùóçò
    5. ÕðÞêïïé ôùí êñáôþí ôïõ Åíéáßïõ Åõñùðáúêïý Ïéêïíïìéêïý ×þñïõ (Å.Å.Ï.×)
    6. ÕðÞêïïé ôùí êñáôþí ðïõ ðåñéëáìâÜíïíôáé óôçí ÅõñùðáúêÞ Óýìâáóç êõñùìÝíç ìå ôï í.ä 4017/1959 (ÖÅÊ/A/246/1959)
    7. ÌåôáíÜóôåò áéôïýíôåò Üóõëï óôçí ÅëëÜäá åöüóïí ðñïóêïìßóïõí óõìðëçñùìáôéêÜ äåëôßï áéôÞóáíôïò Üóõëï óå éó÷ý (Åãêýêëéïò ÕÕÊÁ, 49874-8/4/2009)

    ÐÁÑÁÔÇÑÇÓÅÉÓ:

    * Óôçí Õðåýèõíç äÞëùóç Í. 1599/86 äçëþíïíôáé ôá åîÞò:
    1. ç ïéêïíïìéêÞ åíßó÷õóç èá ÷ñçóéìïðïéåßôáé áðïêëåéóôéêÜ ãéá ôéò áíÜãêåò ôïõ äéêáéïý÷ïõ,
    2. áí ðáßñíåé Þ ü÷é ïéêïíïìéêÞ åíßó÷õóç ãéá ôçí ßäéá áéôßá áðü Üëëï öïñÝá,
    3. ôï Üôïìï ðïõ èá åéóðñÜôôåé ôï åðßäïìá,
    4. üôé èá åíçìåñþíåé ôçí õðçñåóßá ãéá ïðïéáäÞðïôå áëëáãÞ ôùí äçëùèÝíôùí óôïé÷åßùí, üðùò ãíùóôïðïßçóç èáíÜôïõ, ëÞøç ïéêïíïìéêÞò åíßó÷õóçò áðü Üëëï öïñÝá, áëëáãÞ ôüðïõ êáôïéêßáò, åéóáãùãÞ óå ßäñõìá ê.ëð.

    ¾øïò ìçíéáßïõ åðéäüìáôïò áíÜ Ýôïò

    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2002: 357 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2003: 375 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2004: 414 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2005: 460 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2006: 500 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2007: 532 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2008: 569 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2009: 609 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2010: 652 åõñþ
    ¾øïò ìçíéáßïõ åðéäüìáôïò ãéá ôï 2011, 2012, 2013, 2014, 2015, 2016: 697 åõñþ

    ÊñáôéêÞ åðé÷ïñÞãçóç

    Óôï ðáñáðÜíù äéáäñáóôéêü ãñÜöçìá öáßíåôáé ç êñáôéêÞ åðé÷ïñÞãçóç ôùí ÄÞìùí ãéá ôçí êáôáâïëÞ üëùí ôùí ðñïíïéáêþí åðéäïìÜôùí óôïõò äéêáéïý÷ïõò áíÜ äßìçíï áðü ôï ÓåðôÝìâñéï ôïõ 2011 Ýùò óÞìåñá. Ôï äßìçíï ÍïÝìâñéïò - ÄåêÝìâñéïò 2014, äüèçêáí óôïõò äéêáéïý÷ïõò 107 åêáôïììýñéá åõñþ, ôï ìéêñüôåñï óõíïëéêü ðïóü ôùí ôåëåõôáßùí åôþí.

    Óçìåéþóåéò:

    • Ôï åðßäïìá êáôáâÜëëåôáé áíáäñïìéêÜ êÜèå äßìçíï: óôéò 15 Éáíïõáñßïõ, óôéò 15 Ìáñôßïõ, óôéò 15 ÌáÀïõ, óôéò 15 Éïõëßïõ, óôéò 15 Óåðôåìâñßïõ êáé óôéò 15 Íïåìâñßïõ.
    • Ïé äéêáéïý÷ïé ôïõ åðéäüìáôïò õðï÷ñåïýíôáé 1 öïñÜ ôï ÷ñüíï íá ðñïóÝñ÷ïíôáé ìå ôçí ôáõôüôçôÜ ôïõò óôçí áñìüäéá õðçñåóßá êáôüðéí ó÷åôéêÞò åéäïðïßçóçò.

    Íïìïëïãßá:

    ÖÅÊ/640/Â/1982, ÖÅÊ/50/Â/1983, ÖÅÊ/872/Â/1994

  4. ÊÜñôá Ìåôáêßíçóçò Áôüìùí ìå Áíáðçñßåò
  5. Äåëôßï Êïéíùíéêïý Ôïõñéóìïý
  6. ÊÜñôá Ðïëéôéóìïý
  7. Åõêáéñßåò áðáó÷üëçóçò
  8. ÖïñïáðáëëáãÝò
  9. ÅéóáãùãÞ óðïõäáóôþí ÁÌÅÁ
  10. ÁðáëëáãÞ áðü ôç óôñÜôåõóç
  11. ÄùñåÜí áóôéêÝò ôçëåöùíéêÝò êëÞóåéò & Ýêðôùóç Internet
+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò